The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search

Viekira Pak™ (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets)

What is Viekira Pak™?

viekira-pakOn December 19, 2014 the U.S. Food and Drug Administration approved an interferon-free prescription medication, Viekira Pak™ (ombitasvir, paritaprevir, ritonavir and dasabuvir tablets), co-packaged tablets to be taken with or without ribavirin. Viekira Pak™ is indicated for the treatment of patients with genotype 1 chronic hepatitis C infection including those with compensated cirrhosis. It is also approved for HCV/HIV co-infection and for people who have had a liver transplant. It is not for those with advanced cirrhosis (decompensated).

Viekira Pak™ includes:

  • 12.5 mg ombitasvir, a hepatitis C virus NS5A inhibitor,
  • 75 mg paritaprevir, a hepatitis C virus NS3/4A protease inhibitor,
  • 50 mg ritonavir, a CYP3A inhibitor, and
  • 250 mg dasabuvir, a hepatitis C virus non-nucleoside NS5B palm polymerase inhibitor.

Patients take two of the ombitasvir/paritaprevir/ritonavir combination tablets daily in the morning with a meal. The additional dasabuvir tablet is taken twice daily – once in the morning and once in the evening with a meal.

Last Updated: May 2015

Advances in Medications to Treat Hepatitis C., American Liver Foundation. Retrieved May 7, 2015.

Benefits Verification., Retrieved May 7, 2015.

FDA Approves Viekira Pak to Treat Hepatitis C., U.S. Food and Drug Administration. Retrieved May 7, 2015.

Highlights of Prescribing Information - Viekira Pak., AbbVie, Inc. Retrieved May 7, 2015.

proCeed Support Program., Retrieved May 7, 2015.

Viekira Pak (ombitasvir/paritaprevir/ritonavir tablets; dasabuvir tablets)., Retrieved May 7, 2015.